Electronic Aspirin Market Outlook to 2025 Update 2017
The study included 22 patients, of which 70% benefited with the device reporting a 50% reduction in pain over a period of four weeks. The ATI Neurostimulation System was approved by the U.S. FDA for testing in domestic waters in August 2014. Currently the device remains under intensive study and is expected to be thoroughly investigated over a period of several years before it is offered to patients commercially.
View full press release